Literature DB >> 27264176

Innate Immune B Cell Activation by Leishmania donovani Exacerbates Disease and Mediates Hypergammaglobulinemia.

Sasha Silva-Barrios1, Mélina Smans1, Claudia U Duerr2, Salman T Qureshi3, Jörg H Fritz2, Albert Descoteaux1, Simona Stäger4.   

Abstract

Participation of B cells in the immune response by various antibody-independent mechanisms has recently been uncovered. B cells producing cytokines have been described for several infections and appear to regulate the adaptive immune response. B cell activation by Leishmania donovani results in disease exacerbation. How Leishmania activates B cells is still unknown. We show that L. donovani amastigotes activate B cells by triggering endosomal TLRs; this activation leads to the induction of various cytokines. Cytokine expression is completely abrogated in B cells from Ifnar(-/-) mice upon exposure to L. donovani, suggesting an involvement of IFN-I in a positive feedback loop. IFN-I also appears to enhance the expression of endosomal TLRs following exposure to L. donovani. Cell-specific ablation of endosomal TLR signaling in B cells revealed that innate B cell activation by L. donovani is responsible for disease exacerbation through IL-10 and IFN-I production and for the promotion of hypergammaglobulinemia.
Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27264176     DOI: 10.1016/j.celrep.2016.05.028

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  28 in total

1.  IL-4-producing B cells regulate T helper cell dichotomy in type 1- and type 2-controlled diseases.

Authors:  Ramona Hurdayal; Hlumani H Ndlovu; Mélanie Revaz-Breton; Suraj P Parihar; Justin Komguep Nono; Melissa Govender; Frank Brombacher
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-15       Impact factor: 11.205

Review 2.  Redundant and regulatory roles for Toll-like receptors in Leishmania infection.

Authors:  P Chauhan; D Shukla; D Chattopadhyay; B Saha
Journal:  Clin Exp Immunol       Date:  2017-08-07       Impact factor: 4.330

3.  Evaluation of Cysteine Protease C of Leishmania donovani in Comparison with Glycoprotein 63 and Elongation Factor 1α for Diagnosis of Human Visceral Leishmaniasis and for Posttreatment Follow-Up Response.

Authors:  Nicky Didwania; Sarfaraz Ahmad Ejazi; Rudra Chhajer; Abdus Sabur; Saumyabrata Mazumder; Mohd Kamran; Raunak Kar; Krishna Pandey; Vidya Nand Ravi Das; Pradeep Das; Mehebubar Rahaman; Rama Prosad Goswami; Nahid Ali
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

Review 4.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

Review 5.  Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection.

Authors:  Armstrong Murira; Alain Lamarre
Journal:  Front Immunol       Date:  2016-12-19       Impact factor: 7.561

6.  Type I Interferon Impairs Specific Antibody Responses Early during Establishment of LCMV Infection.

Authors:  Matthieu Daugan; Armstrong Murira; Barbara C Mindt; Amélie Germain; Esther Tarrab; Pascal Lapierre; Jörg H Fritz; Alain Lamarre
Journal:  Front Immunol       Date:  2016-12-05       Impact factor: 7.561

Review 7.  Protozoan Parasites and Type I IFNs.

Authors:  Sasha Silva-Barrios; Simona Stäger
Journal:  Front Immunol       Date:  2017-01-19       Impact factor: 7.561

Review 8.  How to master the host immune system? Leishmania parasites have the solutions!

Authors:  Matteo Rossi; Nicolas Fasel
Journal:  Int Immunol       Date:  2018-03-10       Impact factor: 4.823

Review 9.  Close Encounters of Lymphoid Cells and Bacteria.

Authors:  Aranzazu Cruz-Adalia; Esteban Veiga
Journal:  Front Immunol       Date:  2016-10-07       Impact factor: 7.561

Review 10.  Interleukin-4 Receptor Alpha: From Innate to Adaptive Immunity in Murine Models of Cutaneous Leishmaniasis.

Authors:  Ramona Hurdayal; Frank Brombacher
Journal:  Front Immunol       Date:  2017-11-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.